HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of European Patent No. 1989289, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves an in vivo bioreactor scaffolding for cartilage engineering and ex vivo methods of subjecting cells to stress to differentiate them into chondrocytes. The in vivo bioreactor comprises a biodegradable membrane which will subject the cells to conditions that provide a loading regimen on the cells to differentiate them into chondrocytes. The device will also force the differentiation of fibroblast cells in chondrocyte or chondrocyte-like cells for the production of aggrecan, Type II collagen, Sox-9 protein cartilage link protein, and perlecan.
“This European Patent further strengthens our international intellectual property portfolio and cements SpinalCyte as a world leader in this field,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte.
With this addition, SpinalCyte’s portfolio now includes 21 U.S. and foreign patents issued and directly owned by the company, along with 43 patents pending.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 21 U.S. and international issued patents and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement.
